{
    "symbol": "CMPS",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-06 08:04:04",
    "content": " Our groundbreaking Phase 2b trial with COMP360 psilocybin therapy in patients suffering with treatment-resistant depression provide the scientific rationale to announce a robust Phase 3 program, which has now had several clinical sites initiated. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. The long-term follow-up of these two will perhaps enable us to answer some of that what you've asked, but I would expect that you would see, whether it's COMPASS-sponsored post-marketing trials or other potential trials, real-world trials, that actually attempt to answer questions like that around treat to remission or repeat at some point."
}